Consideration of gene therapy for paediatric neurotransmitter diseases
The paediatric neurotransmitter diseases (PNDs) are a group of inborn errors of metabolism characterized by abnormalities of neurotransmitter synthesis or metabolism. Although some children may react favourably to neurotransmitter augmentation treatment, optimal response is not universal and other modes of treatment should be sought. The genes involved in many of the currently known monoamine PNDs have been utilized in pre-clinical and in phase I clinical trials in Parkinson disease (PD) and the basic principles could be applied to the therapy of PNDs with some modifications regarding the targeting and distribution of vectors. However, issues that go beyond neurotransmitter replacement are important considerations in PD and even more so in PNDs. Understanding the pathophysiology of PNDs including abnormal development resulting from the neurotransmitter deficiency will be critical for rational therapeutic approaches. Better animal models of PNDs are necessary to test gene therapy before clinical trials can be attempted.
KeywordsGene Therapy Tyrosine Hydroxylase Parkinson Disease Inborn Error Neuronal Ceroid Lipofuscinosis
aromatic l-amino acid decarboxylase
guanine triphosphate cyclohydrolase I
herpes simplex viruses
paediatric neurotransmitter disease
vesicular monoamine transporter
M.R. is a recipient of a fellowship grant from the Paediatric Neurotransmitter Disease Association. U.J.K. was supported by NIH grant R01NS32080, Parkinson Disease Foundation, and American Parkinson Disease Association for the research described in the review. We thank Keith Hyland for helpful discussions.
The Symposium was supported in part by R13 NS 60363 from the NIH NINDS and Office of Rare Diseases (ORD), and the Johns Hopkins University School of Medicine.
- Azzouz M, Martin-Rendon E, Barber RD, et al (2002) Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson’s disease. J Neurosci 22: 10302–10312.PubMedGoogle Scholar
- Crystal RG, Sondhi D, Hackett NR, et al (2004) Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 15: 1131–1154.PubMedGoogle Scholar
- Davidoff AM, Gray JT, Ng CY, et al (2005) Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 11: 875–888. doi: 10.1016/j.ymthe.2004.12.022.PubMedCrossRefGoogle Scholar
- Laufs S, Kim SH, Kim S, Blau N, Thony B (2000) Reconstitution of a metabolic pathway with triple-cistronic IRES-containing retroviral vectors for correction of tetrahydrobiopterin deficiency. J Gene Med 2: 22–31. doi: 10.1002/(SICI)1521-2254(200001/02)2:1<22::AID-JGM86>3.0.CO;2-1.PubMedCrossRefGoogle Scholar
- Leff SE, Spratt SK, Snyder RO, Mandel RJ (1999) Long-term restoration of striatal l-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson’s disease. Neuroscience 92: 185–196. doi: 10.1016/S0306-4522(98)00741-6.PubMedCrossRefGoogle Scholar
- Lowenstein PR, Mandel RJ, Xiong WD, Kroeger K, Castro MG (2007) Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 7: 347–360. doi: 10.2174/156652307782151498.PubMedCrossRefGoogle Scholar
- Marks WJ Jr, Ostrem JL, Verhagen L, et al (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. Lancet Neurol 7: 400–408. doi: 10.1016/S1474-4422(08)70065-6.PubMedCrossRefGoogle Scholar
- Thony B, Leimbacher W, Stuhlmann H, Heizmann CW, Blau N (1996) Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from hyperphenylalaninemic patients. Hum Gene Ther 7: 1587–1593. doi: 10.1089/hum.1996.7.13–1587.PubMedCrossRefGoogle Scholar